Press & News
Affibody offers collaborations based on Affibody’s proprietary technology platforms, the company’s unique skills and its expertise, and will selectively choose to partner with companies that have therapeutic expertise in relevant disease areas and a significant commitment to development and commercialization of biologics.
Affibodys latest Press releases
Affibody in short
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Upcoming reports Financial calendar
- Year-end report (February 24, 2017)